Qualitative and Quantitative Identification of a New Carbadenafil Analogue in Solid Beverages
  
View Full Text    Download reader
DOI:
KeyWord:coffee  ?carbadenafil analogs  ?illegal addition  ?structure identification  ?quantitative analysis
  
AuthorInstitution
XIA Jin-tao,WU Wan-qin,ZHU Song-song,JIANG Feng,FAN Zhi-yong,WANG Hui-xia,PENG Qing-zhi,YANG Zong 1. Hubei Provincial Engineering and Technology Research Center for Food Quality and Safety Test,Hubei Provincial Institute for Food Supervision and Test,Wuhan ,China;2. SCIEX,Shanghai ,China
Hits: 1110
Download times: 993
Abstract:
      A high performance liquid chromatography - tandem mass spectrometry(HPLC - MS/MS)was developed for the qualitative and quantitative identification of a novel,illegally added and unknown carbadenafil analogue,N-phenylpropoxyphenyl carbadenafil in solid beverages.The sample was firstly identified by using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry(UPLC - Q - TOF MS) and ultra-performance liquid chromatography - linear ion trap/orbitrap high resolution mass spectrometry(UPLC-LTQ/Orbitrap MS).Then the structure of this compound was finally determined as N-phenylpropoxyphenyl carbadenafil by one-dimensional and two-dimensional nuclear magnetic resonance(NMR) spectra and textual comparison.Quantitative analysis was carried out by the external standard method. Results showed that there was a good linear relationship for the analyte in the range of 2 - 50 ng/mL,with correlation coefficient(r2) of 0.999 1.The limit of detection(LOD) and quantification(LOQ) were 0.05 mg/kg and 0.1 mg/kg,respectively. Recoveries at low,medium and high spiked levels ranged from 89.2% to 93.1%, with relative standard deviations(RSD)of 1.8% - 3.1%. Determination on 10 batches of coffee solid beverages revealed that 5 batches of samples were found to be positive,and the contents of N-phenylpropoxyphenyl carbadenafil were between 214 mg/kg and 880 mg/kg. With high accuracy and high efficiency,this method is effective for the screening of illegally added carbadenafil analogs beyond the detection range of current standard.
Close